OPEN END TURBO LONG - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 14:20:09 27/06/2024 BST | ||
| 12.12 EUR / 12.43 EUR | +2.72% |
|
| Current month | +15.46% | ||
| 1 month | +13.92% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 27/06/24 | 11.97 | +0.17% |
| 26/06/24 | 11.95 | +0.67% |
| 25/06/24 | 11.87 | -2.14% |
| 24/06/24 | 12.13 | +3.76% |
| 21/06/24 | 11.69 | -0.60% |
Delayed Quote Börse Stuttgart
Last update June 27, 2024 at 10:51 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MB7J5A |
| ISIN | DE000MB7J5A0 |
| Date issued | 15/06/2023 |
| Strike | 346.3 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.85 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.04 € |
|---|---|
| Lowest since issue | 1.87 € |
| Spread | 0.31 € |
| Spread % | 2.49% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
474
USD
Average target price
468.3
USD
Spread / Average Target
-1.21%
- Stock Market
- Certificates
- Certificat
